Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Athersys, Inc.
  6. Summary
    ATHX   US04744L1061

ATHERSYS, INC.

(ATHX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
1.005(c) 1.1(c) 1.02(c) 1.04(c) 1.03(c) Last
6 277 160 3 517 473 1 924 515 1 761 591 1 126 344 Volume
-11.06% +9.45% -7.27% +1.96% -0.96% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 7,50 M - -
Net income 2021 -84,7 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,71x
Yield 2021 -
Sales 2022 18,8 M - -
Net income 2022 -97,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,81x
Yield 2022 -
Capitalization 242 M 242 M -
Capi. / Sales 2021 32,3x
Capi. / Sales 2022 12,9x
Nbr of Employees 97
Free-Float 91,8%
More Financials
Company
Athersys, Inc. is a biotechnology company that is focused primarily in the field of regenerative medicine. The Company's MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product. The MultiStem cell therapy includes the treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions,... 
More about the company
Ratings of Athersys, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ATHERSYS, INC.
11/19BofA Securities Downgrades Athersys to Neutral From Buy; Price Target is $1.25
MT
11/15ATHERSYS : REPORTS THIRD QUARTER 2021 RESULTS AND PROVIDES CORPORATE UPDATE - Form 8-K
PU
11/15Earnings Flash (ATHX) ATHERSYS Reports Q3 Revenue $4.8M
MT
11/15Athersys, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2021
CI
11/15Athersys Reports Third Quarter 2021 Results and Provides Corporate Update
BU
11/12Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.
BU
10/18ATHERSYS : to Host Third Quarter Financial Results Call
BU
09/28ATHERSYS : to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference
BU
08/10Athersys Partner Completes Enrollment in Phase 2/3 Trial of MultiStem Cell Therapy for ..
MT
08/10ATHERSYS : Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Tr..
BU
08/09ATHERSYS : Reports Second Quarter 2021 Results
BU
08/09Athersys, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/06ATHERSYS' : Partner Reports Favorable Topline Results in Acute Respiratory Distress Syndro..
MT
08/06ATHERSYS : Partner HEALIOS K.K. Announces Positive Topline Results of MultiStem for Acute ..
BU
08/05Athersys, Inc. and Healios K.K. Announce Advancement of Their MultiStem Commercial Part..
CI
More news
News in other languages on ATHERSYS, INC.
11/15Earnings Flash (ATHX) ATHERSYS annonce un chiffre d'affaires de 4,8 millions de dollars..
08/10Un partenaire d'Athersys achève le recrutement pour l'essai de phase 2/3 de la thérapie..
03/30BONE THERAPEUTICS : nouveau directeur scientifique
2018GNW-NEWS : Athersys kündigt Ausbau der Zusammenarbeit mit Healios an
2018ATHERSYS : annonce l'extension de sa collaboration avec Healios
More news
Analyst Recommendations on ATHERSYS, INC.
More recommendations
Chart ATHERSYS, INC.
Duration : Period :
Athersys, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATHERSYS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,03 $
Average target price 3,75 $
Spread / Average Target 264%
EPS Revisions
Managers and Directors
William B. J. Lehmann President, Chief Executive & Operating Officer
Ivor MacLeod Chief Financial & Accounting Officer
Ismail Kola Chairman
John J. Harrington Director, Chief Scientific Officer & Executive VP
Rakesh Ramachandran Head-Information Technology & Communications
Sector and Competitors
1st jan.Capi. (M$)
ATHERSYS, INC.-41.14%242
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678